Skip to content
10-K

Annual Report

Yew Bio-Pharm Group, Inc.

0001213900-20-012320

← back to feed
Filed
May 14, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2019 · May 13, 2020 51.7M sh
Rd Expense FY 2019 · Dec 31, 2019 $0
Rd Expense FY 2019 · Dec 31, 2018 $0
Shares Diluted FY 2019 · Dec 31, 2018 51.97M sh
Capex FY 2019 · Dec 31, 2018 $43.49K
Operating Cash Flow FY 2019 · Dec 31, 2018 $32.47M
Short Term Debt FY 2019 · Dec 31, 2018 $5.76M
Cash And Equivalents FY 2019 · Dec 31, 2018 $521.67K
Cash And Equivalents FY 2019 · Dec 31, 2017 $859.83K
Current Liabilities FY 2019 · Dec 31, 2018 $7.06M
Total Liabilities FY 2019 · Dec 31, 2018 $8.61M
Current Assets FY 2019 · Dec 31, 2018 $12.39M
Total Assets FY 2019 · Dec 31, 2018 $49.69M
Eps Diluted FY 2019 · Dec 31, 2018 −$0.03
Eps Basic FY 2019 · Dec 31, 2018 −$0.03
Sga Expense FY 2019 · Dec 31, 2018 $1.02M
Net Income FY 2019 · Dec 31, 2018 −$1.32M
Operating Income FY 2019 · Dec 31, 2018 $718.6K
Gross Profit FY 2019 · Dec 31, 2018 $10.72M
Cost Of Revenue FY 2019 · Dec 31, 2018 $26.87M
Stockholders Equity FY 2019 · Dec 31, 2017 $45.17M